Anti-tumor compound and preparation method and use thereof
AssigneeDuality Biologics (Suzhou) Co., Ltd.
InventorsYu Zhang, Zhongyuan Zhu, Haiqing Hua, Bing Li, Jian Li, Shengchao Lin, Xi Li, Hongxia Shen
Life of this patent
Estimating the term…
Abstract
The present application relates to an anti-tumor compound and a preparation method and use thereof, and in particular to a compound or a tautomer, a mesomer, a racemate, an enantiomer or a diastereoisomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, and a preparation method and use thereof.
Claims20
A compound of general formula (III-E) or a tautomer, a mesomer, a racemate, an enantiomer or a diastereoisomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof,
- wherein R1 is selected from the group consisting of:
- —O—, —(R2)N— and —S—;
- X is -L1-CH2—C(O)—;
- L1 is —(C(R3a)(R3b))m—;
- wherein R2 is hydrogen, or a C1-6 aliphatic group optionally substituted with R;
- each R3a and each R3b are independently hydrogen, protium, deuterium, tritium, halogen, —NO2, —CN, —OR, —SR, or a C1-6 aliphatic group optionally substituted with R;
- wherein R is hydrogen, protium, deuterium, tritium, halogen, —NO2, —CN, —OH, —SH, or —NH2;
- m is selected from the group consisting of integers from 1 to 5, and R3a and R3b are not both hydrogen in each —C(R3a)(R3b)—.
A compound or a tautomer, a mesomer, a racemate, an enantiomer or a diastereoisomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, wherein the compound comprises the structures selected from the group consisting of:
A compound of general formula (III-F) or a tautomer, a mesomer, a racemate, an enantiomer or a diastereoisomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof,
- wherein, Lx is
- wherein R1 is selected from the group consisting of:
- —O—, —(R2)N— and —S—;
- X is -L1-CH2—C(O)—;
- L1 is —(C(R3a)(R3b))m—;
- wherein R2 is hydrogen or a C1-6 aliphatic group optionally substituted with R, each R3a and each R3b are independently hydrogen, protium, deuterium, tritium, halogen, —NO2, —CN, —OR, —SR, or a C1-6 aliphatic group optionally substituted with R;
- wherein R is hydrogen, protium, deuterium, tritium, halogen, —NO2, —CN, —OH, —SH, or —NH2;
- m is selected from the group consisting of integers from 1 to 5, and R3a and R3b are not both hydrogen in each —C(R3a)(R3b)—.
Dependencies are inferred from the claim text.